Tag Archive for: Sanofi

Nirsevimab lowered hospitalizations due to RSV-related lower respiratory tract disease by 83.21%. Friday’s data drop comes ahead of next week’s advisory committee meeting for Pfizer’s RSV hopeful.

The CEOs of the major insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, which together control 90% of the U.S. market, and top PBM executives from CVS Health, Cigna Group’s Express Scripts, and UnitedHealth Group Inc’s Optum RX, which control 80% of the prescription drug market, will testify.

The companies said in first-quarter earnings calls that they want to restructure R&D, cut costs and shift away from high-risk drug development to focus areas.

Regeneron Pharmaceuticals Inc.’s first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company’s shares more than 5% lower in early trade.

For $150 million upfront, Sanofi will gain access to Maze’s lead asset MZE001, which inhibits the GYS1 protein in the rare genetic disorder.

Sanofi is the latest company to do some spring cleaning of its pipeline. Thursday morning, the pharma announced it will discontinue two acquired programs in its Q1 update.

The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc. of illegally monopolizing the market with its EpiPen auto-injector, a device used to treat severe allergic reactions.

Merck KGaA said on Wednesday the U.S. Food and Drug Administration (FDA) had paused the initiation of new patients on its multiple sclerosis evobrutinib drug, knocking the German drugmaker’s share price.

Sobi has announced a streamlining and simplification of the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca.

Pfizer Inc and GSK are close to bringing the first two vaccines for RSV to the United States after gaining the backing of a panel of advisers to the FDA.